Early findings in a randomised controlled trial on crosslinking protocols using isoosmolar and hypoosmolar riboflavin for the treatment of progressive keratoconus
Acta Ophthalmologica · 2025
DOI: 10.1111/aos.16736 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Acta Ophthalmologica, 2025. Verfasst von Ingemar Gustafsson und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Skåne University Hospital, Malmö, Sweden. Hauptthemen laut MEDLINE: Keratoconus, Riboflavin, Photosensitizing Agents, Cross-Linking Reagents. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Purpose
To present baseline characteristics and to present the perioperative corneal thickness during corneal crosslinking (CXL) treatment for progressive keratoconus and to describe how the addition of sterile water (SW) efficaciously can maintain the corneal thickness. The treatment efficacy will be evaluated when the 1‐year follow‐up is complete.
Methods
A randomised clinical study using epithelium‐off CXL with continuous UVA irradiation (9 mW/cm 2 ) and two kinds of riboflavin solutions: (i) isoosmolar dextran‐based riboflavin ( n = 27) and (ii) hypoosmolar dextran‐free riboflavin ( n = 27). Inclusion criteria: progressive keratoconus with an increase in maximum keratometry value (Kmax) of 1.0 dioptre (12 months) or 0.5 dioptres (6 months). Corneae thinner than 400 μm were also included. Outcome parameters: Perioperative corneal thickness and the effect of adding SW.
Results
Seventy‐four per cent of the patients in the isoosmolar group and 15% in the hypoosmolar group required the addition of SW, which effectively maintained a corneal thickness of 400 μm in all cases during CXL. The addition of SW was primarily needed during the irradiation procedure and not the preoperative soaking period.
Conclusions
Especially during the CXL irradiation phase, isoosmolar riboflavin causes a significant dehydrating effect leading to corneal thinning during CXL. The customised addition of SW is efficacious in maintaining the corneal thickness during CXL and could increase the safety of the procedure.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Ophthalmology, Skåne University Hospital, Malmö, Sweden.
- Department of Clinical Sciences, Lund University, Lund, Sweden.
- Department of Clinical Sciences, Lund University, Malmö, Sweden.
- Department of Ophthalmology, Aarhus University Hospital, Aarhus, Denmark.
ORCID-Profile: Ingemar Gustafsson
Zitieren
APA
Gustafsson, I., Olafsdottir, T., Neumann, O., Johansson, P., Bizios, D., Ivarsen, A., & Hjortdal, J. Ø. (2025). Early findings in a randomised controlled trial on crosslinking protocols using isoosmolar and hypoosmolar riboflavin for the treatment of progressive keratoconus. Acta Ophthalmologica. https://doi.org/10.1111/aos.16736
Vancouver
Gustafsson I, Olafsdottir T, Neumann O, Johansson P, Bizios D, Ivarsen A, et al. Early findings in a randomised controlled trial on crosslinking protocols using isoosmolar and hypoosmolar riboflavin for the treatment of progressive keratoconus. Acta Ophthalmologica. 2025. doi:10.1111/aos.16736
BibTeX
@article{Gustafsson2025,
author = {Gustafsson, Ingemar and Olafsdottir, Thorbjörg and Neumann, Olof and Johansson, Per and Bizios, Dimitrios and Ivarsen, Anders and Hjortdal, Jesper Ø},
title = {Early findings in a randomised controlled trial on crosslinking protocols using isoosmolar and hypoosmolar riboflavin for the treatment of progressive keratoconus},
journal = {Acta Ophthalmologica},
year = {2025},
doi = {10.1111/aos.16736}
}
EUVIMED